Progesterone's Effect on Cholesterol and Weight
The effect of progesterone on LDL cholesterol and total cholesterol depends critically on the type of progestin used—androgenic progestins (like norgestrel, levonorgestrel, and medroxyprogesterone acetate) typically increase LDL cholesterol and decrease HDL cholesterol, while newer-generation, less androgenic progestins (desogestrel, norgestimate, gestodene) tend to lower LDL cholesterol and raise HDL cholesterol. 1
Lipid Effects by Progestin Type
Androgenic Progestins (Unfavorable Profile)
The following progestins exert androgenic activity and worsen lipid profiles:
- Norgestrel and levonorgestrel: Usually increase LDL-cholesterol and decrease HDL-cholesterol 1
- Medroxyprogesterone acetate (MPA): Also increases LDL and decreases HDL 1
These changes are clinically significant because they shift the lipid profile toward a more atherogenic pattern, potentially increasing cardiovascular risk.
Non-Androgenic Progestins (Favorable Profile)
Newer-generation progestins with less androgenic activity show opposite effects:
- Desogestrel, norgestimate, gestodene: Tend to raise HDL-cholesterol and lower LDL-cholesterol 1
- In a meta-analysis of 18 studies, desogestrel increased HDL by 0.058 g/L and reduced LDL by 0.045 g/L 1
Natural Progesterone
When combined with estrogen therapy, natural progesterone causes less attenuation of estrogen's beneficial HDL-raising effect compared to synthetic progestins like MPA 2. The 2020 Endocrine Society guidelines note that progestins tend to decrease HDL-C levels, and combined estrogen-progesterone therapy blunts lipid changes compared to estrogen alone 3.
Clinical Thresholds
Important safety thresholds from French Society of Endocrinology guidelines 1:
- LDL cholesterol >2.20 g/L (approximately 170 mg/dL) contraindicates estrogen-progestin contraception in women without cardiovascular risk factors
- With each additional risk factor, lower the threshold by 0.30 g/L
- Progestin-only contraception remains feasible above this threshold, preferably using compounds without significant androgenic activity
Weight Loss Considerations
Regarding weight loss difficulty: The provided evidence does not directly address progesterone's effect on weight loss or metabolic rate. However, the evidence shows:
- Progestins can affect insulin sensitivity, with some studies showing worsening insulin resistance 3
- The type of progestin matters significantly for metabolic effects
- Androgenic progestins create a more unfavorable metabolic profile overall
Common Pitfalls to Avoid
- Not distinguishing progestin type: Assuming all progestins have identical effects on lipids is incorrect—the androgenic potency determines the lipid impact
- Ignoring baseline lipid levels: Women with LDL >2.20 g/L should not receive combined hormonal contraception but can use progestin-only methods with non-androgenic compounds 1
- Failing to monitor: Lipid profiling should be done 3-6 months after starting hormonal contraception 1
Practical Algorithm
If prescribing progesterone/progestin therapy:
- Check baseline lipids before starting therapy
- Choose progestin based on lipid profile:
- If LDL is elevated or borderline: Use non-androgenic progestins (desogestrel, norgestimate, gestodene) or natural progesterone
- Avoid androgenic progestins (norgestrel, levonorgestrel, MPA) in women with dyslipidemia
- Recheck lipids at 3-6 months after initiation 1
- Discontinue if LDL exceeds thresholds based on cardiovascular risk factors 1
The FDA label for progesterone capsules does not specifically list dyslipidemia or weight gain as major adverse effects, though it notes the importance of cardiovascular monitoring when combined with estrogen 4.